⚕ GalenOps CRO console
← SITE013 (USA)

SITE013-0173

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE013 (USA) (Dr. Clarke) · consented 2022-09-17
Adverse events
6
Serious AEs
2
Open data queries
0
Luna dropout signal
–

Adverse events

severe serious assessed 2026-08-18

Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-11-02 (study day 32); relationship: not assessed; serious criteria: life-threatening

mild assessed 2026-08-18

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-12-26 (study day 86); relationship: Y

severe assessed 2026-08-18

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-12 (study day 103); relationship: N

severe serious assessed 2026-08-18

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-01-25 (study day 116); relationship: not assessed; serious criteria: hospitalization

moderate assessed 2026-08-18

Grade 2 Decreased appetite — outcome: UNKNOWN; onset 2023-04-25 (study day 206); relationship: Y

severe assessed 2026-08-18

Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-09-14 (study day 348); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.